Information Hub

Clinical News

2020-11-20

A new oral SERD drug, SAR439859, shown the anti-tumor activity in ER+/Her2- breast cancer

SAR439859 is a new oral SERD drug. A phase I/II study shown the anti-tumor activity of SAR439859 in ER+/Her2- breast cancer patients previously treated with hormone therapy.

Source:

Annals of Oncology

2020-11-20

Adagrasib (MRTX849) showed efficacy and safety in KRASG12C NSCLCs from KRYSTAL-1 study

Adagrasib was a well tolerated drug and demonstrated 45% objective responds and 96% of disease control rate in the heavily pre-treated KRASG12C mutant NSCLC patients.

Source:

EORTC-NCI-AACR 2020

2020-11-20

CH5126766 is a novel potential treatment for RAS/RAF mutant cancers

A small molecular inhibitor of RAF-MEK, CH5126766, showed its potential for treating RAS/RAF-mutant solid tumors in a phase 1 study.

Source:

Lancet Oncol. 2020

2020-10-22

The biomarker exploratory analyzed results of the phase 3 JAVELIN Bladder 100 trial

Avelumab plus best supportive care (BSC) was demonstrated to prolong overall survival with first-line maintenance treatment in advanced urothelial carcinoma (UC) in phase 3 JAVELIN Bladder 100 trial. An exploratory analysis indicated that the combination

Source:

Annals of Oncology

2020-10-22

Poziotinib showed potential in treating NSCLC patients harboring an ERBB2 Exon 20 insertion

In phase 2 ZENITH20 trial, poziotinib demonstrated anti-tumor activity in NSCLC patients who had an ERBB2 Exon 20 Insertion. Tumor reduction in 74% of patients.

Source:

Annals of Oncology

2020-10-22

An EGFR-MET bispecific antibody-Amivantamab(JNJ-372) combine with 3rd generation EGFR TKI-Lazertinib demonstrated safety and efficacy in a phase I trial

The combination of amivantamab and lazertinib showed 36% ORR in Osimertinib resistant patients and 100% ORR in treatment naïve EGFR+ NSCLC patients with favorable safety profile.

Source:

Annals of Oncology

2020-09-22

A case series study of cancers with NRG1 gene fusion

A case series study described six cancer patients with NRG1 gene fusion received afatinib treatment. Four patients achieved partial response. The results indicated NRG1 gene fusion is a potential druggable biomarker in clinical practice.

Source:

Oncologist

2020-09-22

Olaparib and Durvalumab Combination Showed Promising Results in HER2-negative Breast Cancer Patients with Germline BRCA Mutation

MEDIOLA is a phase I/II basket trial of olaparib and durvalumab. In a study cohort of the MEDIOLA study, the combination of olaparib and durvalumab showed promising anti-tumor activity in HER2-negative gBRCA-mutated breast cancer.

Source:

Lancet Oncol.

2020-09-22

Ensartinib: A new TKI inhibitor prolonged PFS in ALK+ NSCLC patients

In a phase 3 study (eXalt3), ensartinib showed longer mPFS and higher intracranial ORR compared with crizotinib. The results indicated ensartinib can be a new first-line treatment option for patients with ALK+ NSCLC.

Source:

IASLC WCLC 2020

2020-08-21

A new IDH1/2 inhibitor for mutated IDH1/2 low-grade glioma

In a phase I study, the anti-tumor activity of vorasidenib (VOR; AG-881) was demonstrated in mutated IDH1/2 low-grade glioma.

Source:

J Clin Oncol